Dinaciclib - CAS# 779353-01-4 ram Potassium otastat

Potassium otastat

which is followed by apoptotic cell death

PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance

NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice

decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines

Dinaciclib - CAS# 779353-01-4 ram Potassium otastatDinaciclib, also known as SCH727965, is a potent CDK inhibitor with potential antineoplastic activity. Dinaciclib selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9 activity in vitro with IC(50) values of 1, 1, 3, and 4 nmol L, respectively. Compared with flavopiridol, Dinaciclib exhibits superior activity with an improved therapeutic index. Dinaciclib induced regression of established solid tumors in a range of mouse models